VIDEO: Approaching EGFR exon 19 deletion, L858R mutations in lung cancer

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

So, both EGFR 19 deletion and the L858R are synthesizing mutations. So, they both allow patients who have this mutations in a tumor to be treated with EGFR tyrosine kinase inhibitors. You know, as been described that exon 19 deletion has a longer survival, you know, longer response to EGFR tyrosine kinase inhibitors. However, you know, in our practice we all have patients who actually have very good outcomes also with the exon 21 858R mutation. So, I would not, you know, focus specifically.

One thing that I think it is important, it's the histology. So, the majority of EGFR mutations, they arise in lung adenocarcinomas, but there are few, there's a small percentage of patients with squamous cell carcinoma of the lungs that actually have EGFR mutation. There's been a recent publication, and we've also observed it in our practice actually, that the squamous histology might actually predict for a shorter time to response to the EGFR tyrosine kinase inhibitor. So, I would say probably, I would give more importance to the histology other than, you know, the specific sensitizing mutation. EGFR exon 19 has been associated with a longer response.